(Q40418250)

20 September 2017

1 reference

title

Electrophysiologic and proarrhythmic effects of intravenous inotropic agents (English)

1 reference

20 September 2017

Tisdale JE

1

1 reference

20 September 2017

Patel R

2

1 reference

20 September 2017

Webb CR

3

1 reference

20 September 2017

Borzak S

4

1 reference

20 September 2017

Zarowitz BJ

5

1 reference

20 September 2017

1 September 1995

1 reference

Progress in Cardiovascular Diseases

20 September 2017

1 reference

20 September 2017

38

1 reference

20 September 2017

2

1 reference

20 September 2017

167-180

1 reference

Effects of dobutamine on electrophysiological properties of the specialized conduction system in man

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Effects of DPI 201-106, a novel cardiotonic agent, on hemodynamics, cardiac electrophysiology and arrhythmias induced by programmed ventricular stimulation in dogs with subacute myocardial infarction: A comparative study with dobutamine

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Direct effect of dobutamine on action potential duration in ischemic compared with normal areas in the human ventricle

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Differential adrenergic sensitivity of atrial and ventricular tissue assessed by chronotropic, inotropic, and cyclic AMP responses to isoprenaline and dobutamine

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Dobutamine: development of a new catecholamine to selectively increase cardiac contractility

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparative cardiac dynamic effects of dobutamine and isoproterenol in conscious instrumented dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparative Effects of Prenalterol and Dobutamine in a Canine Model of Acute Ischemic Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Dobutamine and general anaesthesia: A study of the response of arterial pressure, heart rate and renal blood flow

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparative systemic and regional hemodynamic effects of dopamine and dobutamine

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

A comparison of the hemodynamic effects of inotropic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparison of the effects of amrinone and dobutamine on hemodynamics and myocardial oxygen balance in dogs with experimental left ventricular failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Effect of dopexamine hydrochloride in the early stages of experimental myocardial infarction and comparison with dopamine and dobutamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Clinical cardiovascular pharmacology of dobutamine. A selective inotropic catecholamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Hemodynamic effect of dobutamine in patients with severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Influence of dobutamine on hemodynamics and coronary blood flow in patients with and without coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparison of dobutamine and dopamine in treatment of severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Cardiovascular effects of dobutamine in severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Efficacy of dopamine, dobutamine, and epinephrine during emergence from cardiopulmonary bypass in man

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

A comparison of digoxin and dobutamine in patients with acute infarction and cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Tolerance to dobutamine after a 72 hour continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparison of dopamine and dobutamine following coronary artery bypass grafting.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparative vasoactive therapy for heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Augmentation of cardiac function in end-stage heart failure by combined use of dobutamine and amrinone

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Predicting the extent and location of coronary artery disease in acute myocardial infarction by echocardiography during dobutamine infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparison of the effects of dopamine, dobutamine, and dopexamine upon renal blood flow: a study in normal healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Effect of dobutamine on plasma potassium in congestive heart failure secondary to idiopathic or ischemic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Dobutamine and improvement of regional and global left ventricular function in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Arrhythmias associated with intermittent outpatient dobutamine infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Sympathomimetic drugs and repolarization of ventricular myocardium of the dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

The effect of sympathomimetic amines on the ventricular fibrillation threshold in the rabbit isolated heart

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Evaluation of the Effect of Dopamine and Other Catecholamines on the Electrocardiogram and Blood Pressure of Rats by Means of On-line Biosignal Processing

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Dopamine in the conscious dog with chronic heart-block. Mechanisms of chronotropic cardiac effects

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Arrhythmogenicity of dopamine and its effects on hemodynamics in dogs under halothane anesthesia

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

A comparative study on the influence of dopamine and metaproterenol on the ventricular fibrillation threshold in cats

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

A Hemodynamic Comparison of Dopamine and Isoproterenol in Patients in Shock

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Dopamine: its potential for inducing ischemic left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparison of hemodynamic and oxygen transport effects of dopamine and dobutamine in critically ill surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Postoperative arrhythmias and risk factors after open heart surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Hemodynamic comparison of dopexamine hydrochloride and dopamine in ischemic left ventricular dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Provocation of coronary spasm by dopamine in patients with active variant angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Treatment of circulatory shock with dopamine. Studies on survival

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one]

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Effects of amrinone on atrioventricular conduction in the intact canine heart

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Electrophysiological Actions of Amrinone in Dogs with Cardiac Lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Cardiac effects of amrinone on rabbit papillary muscle and guinea pig Langendorff heart preparations.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

The effect of milrinone (Win 47203) on the in vitro electropharmacological properties of mammalian cardiac tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

The effects of milrinone on action potential characteristics, conduction, automaticity, and reflected reentry in isolated myocardial fibers.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

The effects of milrinone on conduction, reflection, and automaticity in canine Purkinje fibers

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Electrophysiology of phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Electrophysiologic effects of milrinone in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Arrhythmogenic potencies of amrinone and milrinone in unanesthetized dogs with myocardial infarct

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Milrinone. A clinical trial in 29 dogs with moderate to severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Hemodynamic assessment of amrinone. A new inotropic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Intravenous use of amrinone for the treatment of the failing heart

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Long term survival of class IV heart failure patients treated with oral amrinone

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Amrinone and exercise performance in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Intravenous milrinone in patients with severe congestive cardiac failure awaiting heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

The use of intravenous milrinone in chronic symptomatic ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Effects of milrinone on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Effects of dobutamine in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

Cardiorespiratory failure in toxic shock syndrome: effect of dobutamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980005-2

7 January 2021

10.1016/S0033-0620(05)80005-2

Identifiers

DOI

1 reference

20 September 2017

1 reference